Illumina News and Research

RSS

Clontech Laboratories announces launch of DNA SMART ChIP-Seq Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the DNA SMART ChIP-Seq Kit. This kit adapts Clontech's patented SMART technology in an innovative manner for use with low-input samples, including both dsDNA and ssDNA templates, to generate ChIP-seq libraries for NGS.

23 Sep 2014

Cypher Genomics, Illumina partner to facilitate development of genomic-based biomarkers

Cypher Genomics, Inc., the genome informatics company, announced today a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.

From Illumina, Inc. 24 Jul 2014

New York State DOH grants RPCI approval to begin genomic testing of cancer patients

The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.

21 Jul 2014

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies.

12 Jun 2014

Rubicon signs agreements with 7 distributors to expand availability of DNA library preparation products

Rubicon Genomics, Inc., today announced that it signed agreements with seven distributors in Europe to expand the availability of its leading DNA library preparation products, including ThruPLEX®-FD Prep Kit and PicoPLEX™ DNA-seq Kit for use with Illumina® next-generation sequencing (NGS) systems and PicoPLEX™ WGA Kit for use on arrays, and to prepare for new product launches planned for the coming months.

9 Jun 2014

Illumina launches VeriSeq PGS for preimplantation genetic screening of embryos

Illumina, Inc. today announced the launch of VeriSeq PGS, a next-generation sequencing solution developed for preimplantation genetic screening of embryos using Illumina's NextSeq 500 and MiSeq® sequencing systems.

From Illumina, Inc. 29 Apr 2014

UM researchers awarded FDA contract to expand high-throughput sequencing database

Researchers at the Institute for Genome Sciences at the University of Maryland School of Medicine have been awarded a research program contract from the U.S. Food and Drug Administration (FDA) to sequence, assemble, and annotate a population of bacterial pathogens using two high-throughput sequencing (HTS) technologies in support of the expansion of a vetted public reference database.

2 Apr 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

cfDNA testing lowers false positive rates and higher predictive values in general obstetric population

A study in this week's New England Journal of Medicine potentially has significant implications for prenatal testing for major fetal chromosome abnormalities. The study found that in a head-to-head comparison of noninvasive prenatal testing using cell free DNA (cfDNA) to standard screening methods, cfDNA testing (verifi- prenatal test, Illumina, Inc.) significantly reduced the rate of false positive results and had significantly higher positive predictive values for the detection of fetal trisomies 21 and 18.

From Illumina, Inc. 27 Feb 2014

The Future of DNA Sequencing

In this interview, Barret Bready discusses the current gold standards in DNA sequencing and how the Nabsys platform is revolutionizing this process.

18 Feb 2014

Novogene purchases HiSeq X Ten sequencing system from Illumina

Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn), a leading genomics service provider based in Beijing, China, purchased one HiSeq X Ten.

From Illumina, Inc. 13 Feb 2014

CHOP develops unique laboratory test to characterize genes that encode HLA molecules

Immunogenetics experts at The Children's Hospital of Philadelphia (CHOP) have developed a unique laboratory test to characterize the genes that encode HLA molecules. The test relies on faster, more comprehensive gene sequencing technology to type human leukocyte antigens (HLAs)--complex, highly variable proteins on cell surfaces that are essential to immune function.

13 Feb 2014

Rubicon Genomics introduces PicoPLEX DNA-seq Kits for use with Illumina NGS platforms

Rubicon Genomics, Inc. today announced the launch of its PicoPLEX DNA-seq Kits for use with Illumina next-generation sequencing (NGS) platforms. PicoPLEX's outstanding robustness and reproducibility have made it the worldwide standard for single-cell DNA amplification for microarray and PCR-based pre-implantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables researchers and clinicians to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

10 Feb 2014

Illumina inks multi-year supply agreement with LabCorp

Illumina, Inc. today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America Holdings. The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

From Illumina, Inc. 21 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing, today announces that it is launching a CE/IVD labeled MID kit for Illumina MiSeq together with three new germline mutation detection MASTRTM kits enabling the identification of individuals at risk for maturity onset diabetes of the young, autosomal dominant hypercholesterolemia, and hypertrophic cardiomyopathy.

2 Dec 2013

Illumina News and Research

Clontech Laboratories announces launch of DNA SMART ChIP-Seq Kit

Cypher Genomics, Illumina partner to facilitate development of genomic-based biomarkers

New York State DOH grants RPCI approval to begin genomic testing of cancer patients

DNA methylation identified as potential anti-TNF response biomarker for RA

Rubicon signs agreements with 7 distributors to expand availability of DNA library preparation products

Illumina launches VeriSeq PGS for preimplantation genetic screening of embryos

UM researchers awarded FDA contract to expand high-throughput sequencing database

Trovagene reports net loss of $1 million for fourth quarter 2013

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

cfDNA testing lowers false positive rates and higher predictive values in general obstetric population

The Future of DNA Sequencing

Novogene purchases HiSeq X Ten sequencing system from Illumina

CHOP develops unique laboratory test to characterize genes that encode HLA molecules

Rubicon Genomics introduces PicoPLEX DNA-seq Kits for use with Illumina NGS platforms

Illumina inks multi-year supply agreement with LabCorp

Illumina signs multi-year licensing agreement with Quest Diagnostics

Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

Illumina announces launch of TruGenome Undiagnosed Disease Test

U.K. Organizations Partner With Illumina To Sequence 10,000 Whole Genomes

New collaborative project aims to discover genes underlying rare genetic diseases

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News